Results 211 to 220 of about 2,763,581 (350)

The Efficacy and Safety of High-Dose Nonsedating Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of Randomized Clinical Trials

open access: green, 2022
Xianjun Xiao   +11 more
openalex   +1 more source

Exploring the Disease Duration of Urticaria and Associated Determinants in Primary Care

open access: yes
Clinical &Experimental Allergy, EarlyView.
R. Soegiharto   +6 more
wiley   +1 more source

Efficacy of an intervention to reduce stigma towards people with skin diseases among health and body care professionals – a randomized controlled trial

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives People with skin disease often experience stigmatization in health and body care settings, significantly impacting their quality of life. This parallel‐group randomized controlled trial evaluated a face‐to‐face group seminar aimed at reducing stigma towards people with skin disease among health and body care ...
Juliane Traxler   +5 more
wiley   +1 more source

Drug Allergy Risk Stratification in Children With Immediate or Delayed Urticaria During Antibiotic Treatment

open access: yes
Clinical &Experimental Allergy, EarlyView.
Francesca Mori   +8 more
wiley   +1 more source

Digital health applications, telemedicine and large language models in dermatology: results of a Germany‐wide survey

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Abstract Background: Digital technologies offer opportunities for dermatological care, but there is a lack of systematic data on their use and acceptance, particularly with regard to digital health applications (DiGA) and large language models (LLMs).
Lukas Henk   +9 more
wiley   +1 more source

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy